# Novartis AG (NVS)

- Sector: Healthcare · Industry: Drug Manufacturers General
- SEC CIK: 0001114448 ([filings on EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001114448))
- Full page: https://inspectstocks.com/stocks/nvs
- Data as of: price 2026-09-25; newest filing used 2026-07-21; latest fiscal period ended 2026-06-30

## Grade

**A** on the growth-and-cash rubric, 5 of 5 checks passed.

| Check | Result | Now | Before |
| --- | --- | --- | --- |
| Revenue growing overall | passed | $56.7B | $11.6B |
| Revenue growing recently | passed | $56.7B | $51.7B |
| Free cash flow positive | passed | $17.6B |  |
| Free cash flow growing overall | passed | $17.6B | $13.3B |
| Free cash flow growing recently | passed | $17.6B | $16.3B |

Business quality (the + / − mark): 2 of 6 checks passed.

| Check | Result | Now | Before |
| --- | --- | --- | --- |
| Profitable | failed | -0.1% |  |
| Healthy profit margin | failed | -0.1% |  |
| Strong operating margin | failed | 0.0% |  |
| Good return on equity | failed | -0.1% |  |
| Debt under control | passed | 0.07 |  |
| Turns sales into cash | passed | 31.0% |  |

How the grade works: the letter counts failed checks (none → A, one → B, two → C, three → D, four or more → F). It is built from SEC filings only — the share price never enters it — and describes the business, not whether the stock is worth buying.

## Key figures

In US dollars, as filed.

| Measure | Value |
| --- | --- |
| Revenue, trailing twelve months | $56.7B |
| Net income, trailing twelve months | -$45M |
| Free cash flow, trailing twelve months | $17.6B |
| Net margin | -0.1% |
| Operating margin | 0.0% |
| Return on equity | -0.1% |
| Debt to equity | 0.07 |
| Diluted EPS, trailing twelve months | $7.15 |
| Share price | $145.46 |
| Market value | $277.6B |
| Price / earnings | 20.3x |
| Price / sales | 4.9x |

## More on this company

- [Overview](https://inspectstocks.com/stocks/nvs)
- [Financial statements](https://inspectstocks.com/stocks/nvs/financials)
- [Competitors](https://inspectstocks.com/stocks/nvs/peers)
- [Earnings](https://inspectstocks.com/stocks/nvs/earnings)

---

Source: InspectStocks, built from the company’s own SEC filings. This describes a business — it is not investment advice and not a recommendation to buy or sell anything.